Turning Cold Tumors Hot

About Us

Kineta, Immuno-Oncology is a privately held biotech company focused on developing disruptive technologies that shift the paradigm in cancer treatment by turning cold tumors hot.  Our research and development is centered around small molecule innate immune activators of the RIG-I pathway.  This novel pathway has been largely unexploited for drug discovery.  Activating innate immune pathways can cause direct tumor killing and an anti-tumor immune response.

Kineta Immuno-oncology was established in 2016.  Our novel technology was originally discovered through the innate immune screening platform developed by Kineta, Inc. and supported by funding from the National Institutes of Health (NIH).